隨著腫瘤對(duì)人類(lèi)健康的威脅逐漸加大，人類(lèi)對(duì)癌癥的細(xì)胞生物學(xué)和生物醫(yī)學(xué)研究有了飛速的發(fā)展，癌基因、抑癌基因、細(xì)胞凋亡、腫瘤血管形成等使腫瘤研究由細(xì)胞生物學(xué)水平轉(zhuǎn)變到分子生物學(xué)水平[1]。以膜上或細(xì)胞內(nèi)特異性表達(dá)或高表達(dá)的分子為作用靶點(diǎn)，包括靶向酪氨酸激酶，血管新生，腫瘤細(xì)胞周期相關(guān)因子，組蛋白去乙酰酶抑制劑，微環(huán)境，腫瘤干細(xì)胞，腫瘤代謝異常等因素成為研究靶點(diǎn)特異性抗腫瘤藥物的關(guān)鍵[2]。百靈威作為專(zhuān)業(yè)試劑供應(yīng)商，可提供120余種腫瘤研究靶點(diǎn)抑制劑和激活劑產(chǎn)品。
- 多種熱門(mén)靶點(diǎn)抑制劑，滿(mǎn)足前沿科研需求
- 作用靶點(diǎn)清晰，易于客戶(hù)選擇
- 產(chǎn)品純度高，質(zhì)量穩(wěn)定，現(xiàn)貨供應(yīng)
.png)
圖1:Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002[3].
References
[1] Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria[J]. Nature, 2015, 520(7549):683-7.
[2] Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, Lord JM: Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence[J]. Blood. 2014,123(2):239-248.
[3] To K K W, Tomlinson B. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists[J]. British Journal of Pharmacology, 2013, 170(5):1137–1151.
■ 腫瘤研究化合物
|
產(chǎn)品編號(hào)
|
英文名稱(chēng)
|
中文名稱(chēng)
|
CAS
|
作用靶點(diǎn)
|
|
150037
|
5-Azacytidine, 99%
|
5-氮雜胞嘧啶核苷, 99%
|
320-67-2
|
DNA Methyltransferase抑制劑
|
|
268355
|
2-Amino-6-purinethiol, 98%
|
2-氨基-6-嘌呤硫醇, 98%
|
154-42-7
|
DNA Methyltransferase抑制劑
|
|
180939
|
5-Fluorouracil, 99%
|
5-氟尿嘧啶, 99%
|
51-21-8
|
DNA/RNA Synthesis抑制劑
|
|
251696
|
Oxaliplatin, 95%
|
奧沙利鉑, 95%
|
61825-94-3
|
DNA/RNA Synthesis抑制劑
|
|
258050
|
2-Chloro-2'-deoxyadenosine, 99%
|
2-氯-2'-脫氧腺苷, 99%
|
4291-63-8
|
DNA/RNA Synthesis抑制劑
|
|
271269
|
Gemcitabine hydrochloride, 99%
|
鹽酸吉西他濱, 99%
|
122111-03-9
|
DNA/RNA Synthesis抑制劑
|
|
274584
|
Carboplatin, 98%
|
碳鉑, 98%
|
41575-94-4
|
DNA/RNA Synthesis抑制劑
|
|
275688
|
cis-Diamineplatinum(II) dichloride, 99%
|
順式-二氨二氯化鉑, 99%
|
15663-27-1
|
DNA/RNA Synthesis抑制劑
|
|
381488
|
Ara-G hydrate, 98%
|
阿糖鳥(niǎo)苷, 98%
|
38819-10-2
|
DNA/RNA synthesis抑制劑
|
|
341249
|
Erlotinib, 98%
|
埃羅替尼, 98%
|
183321-74-6
|
EGFR抑制劑
|
|
795123
|
Lapatinib ditosylate, 98%
|
二甲苯磺酸拉帕替尼, 98%
|
388082-77-7
|
EGFR抑制劑
|
|
831262
|
Lapatinib, 98%
|
拉帕替尼, 98%
|
231277-92-2
|
EGFR抑制劑
|
|
996037
|
Afatinib, 98%
|
阿法替尼, 98%
|
850140-72-6
|
EGFR抑制劑
|
|
303595
|
Trichostatin A, 98%
|
曲古柳菌素A, 98%
|
58880-19-6
|
HDAC抑制劑
|
|
628151
|
Vorinostat, 99%
|
伏立諾他, 99%
|
149647-78-9
|
HDAC抑制劑
|
|
625238
|
Entinostat, 99%
|
恩替諾特, 99%
|
209783-80-2
|
HDAC抑制劑
|
|
837002
|
Panobinostat, 98%
|
帕比司他, 98%
|
404950-80-7
|
HDAC抑制劑
|
|
1349106
|
Ruxolitinib phosphate salt, 99%
|
魯索利替尼磷酸鹽, 99%
|
1092939-17-7
|
JAK抑制劑
|
|
1430418
|
Tofacitinib citrate, 99%
|
檸檬酸托法替尼, 99%
|
540737-29-9
|
JAK抑制劑
|
|
912849
|
Tofacitinib, 99%
|
托法替尼, 99%
|
477600-75-2
|
JAK抑制劑
|
|
951485
|
Ruxolitinib, 99%
|
魯索替尼, 99%
|
941678-49-5
|
JAK抑制劑
|
|
1272662
|
Cabazitaxel, 99%
|
卡巴他賽, 99%
|
183133-96-2
|
Microtubule Associated抑制劑
|
|
181603
|
Docetaxel, 98%
|
多西他賽, 98%
|
114977-28-5
|
Microtubule Associated抑制劑
|
|
266725
|
Combretastatin A-4, 98%
|
康普瑞汀, 98%
|
117048-59-6
|
Microtubule Associated抑制劑
|
|
369172
|
6-Amino-3-methylpurine, 90%
|
6-氨基-3-甲基嘌呤, 90%
|
5142-23-4
|
PI3K抑制劑
|
|
268623
|
Quercetin, 98%
|
槲皮素, 98%
|
117-39-5
|
PI3K抑制劑
|
|
114089
|
7-Ethyl-10-hydroxycamptothecin, 99%
|
7-乙基-10-羥基喜樹(shù)堿, 99%
|
86639-52-3
|
Topoisomerase抑制劑
|
|
116557
|
Daunorubicin hydrochloride, 97%
|
道諾霉素鹽酸鹽, 97%
|
23541-50-6
|
Topoisomerase抑制劑
|
|
194237
|
Epirubicin hydrochloride, 98%
|
表柔比星鹽酸鹽, 98%
|
56390-09-1
|
Topoisomerase抑制劑
|
|
814262
|
Vandetanib, 99%
|
凡德他尼, 99%
|
443913-73-3
|
VEGFR2抑制劑
|
|
1109982
|
Vatalanib dihydrochloride, 99%
|
瓦他拉尼堿二鹽酸鹽, 99%
|
212141-51-0
|
VEGFR2抑制劑
|
|
1239124
|
Ponatinib, 99%
|
帕納替尼, 99%
|
943319-70-8
|
VEGFR2抑制劑
|
|
812864
|
Axitinib, 98%
|
阿西替尼, 98%
|
319460-85-0
|
VEGFR2抑制劑
|
|
1386067
|
A 769662, 98%
|
A 769662, 98%
|
844499-71-4
|
AMPK激活劑
|
■ 相關(guān)產(chǎn)品：